These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 11985528)

  • 21. Safety and immunogenicity of REMUNE in HIV-infected Thai subjects.
    Limsuwan A; Churdboonchart V; Moss RB; Sirawaraporn W; Sutthent R; Smutharaks B; Glidden D; Trauger R; Theofan G; Carlo D
    Vaccine; 1998; 16(2-3):142-9. PubMed ID: 9607022
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic immunisation plus cytokine and hormone therapy improves CD4 T-cell counts, restores anti-HIV-1 responses and reduces immune activation in treated chronic HIV-1 infection.
    Herasimtschuk A; Downey J; Nelson M; Moyle G; Mandalia S; Sikut R; Adojaan M; Stanescu I; Gotch F; Imami N
    Vaccine; 2014 Dec; 32(51):7005-7013. PubMed ID: 25454870
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunologic and virologic response after tetanus toxoid booster among HIV-1- and HIV-2-infected Senegalese individuals.
    Dieye TN; Sow PS; Simonart T; Guèye-Ndiaye A; Popper SJ; Delforge ML; Dieye A; Sarr AD; Crusiaux A; Van Vooren JP; Devleeschouwer M; Kanki P; Mboup S; Diakhate L; Farber CM
    Vaccine; 2001 Dec; 20(5-6):905-13. PubMed ID: 11738756
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A double-blind, adjuvant-controlled trial of human immunodeficiency virus type 1 (HIV-1) immunogen (Remune) monotherapy in asymptomatic, HIV-1-infected thai subjects with CD4-cell counts of >300.
    Churdboonchart V; Sakondhavat C; Kulpradist S; Na Ayudthya BI; Chandeying V; Rugpao S; Boonshuyar C; Sukeepaisarncharoen W; Sirawaraporn W; Carlo DJ; Moss R
    Clin Diagn Lab Immunol; 2000 Sep; 7(5):728-33. PubMed ID: 10973445
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New strategies to combat HIV: augmenting antiviral immunity.
    Smith KA; Boyle BA
    AIDS Read; 2003 Aug; 13(8):365-9, 382. PubMed ID: 14524321
    [No Abstract]   [Full Text] [Related]  

  • 26. HIV-1 Reservoir Dynamics after Vaccination and Antiretroviral Therapy Interruption Are Associated with Dendritic Cell Vaccine-Induced T Cell Responses.
    Andrés C; Plana M; Guardo AC; Alvarez-Fernández C; Climent N; Gallart T; León A; Clotet B; Autran B; Chomont N; Gatell JM; Sánchez-Palomino S; García F
    J Virol; 2015 Sep; 89(18):9189-99. PubMed ID: 26109727
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gene combination raises broad human immunodeficiency virus-specific cytotoxicity.
    Calarota SA; Kjerrström A; Islam KB; Wahren B
    Hum Gene Ther; 2001 Sep; 12(13):1623-37. PubMed ID: 11535166
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4(+) T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial.
    Ensoli B; Nchabeleng M; Ensoli F; Tripiciano A; Bellino S; Picconi O; Sgadari C; Longo O; Tavoschi L; Joffe D; Cafaro A; Francavilla V; Moretti S; Pavone Cossut MR; Collacchi B; Arancio A; Paniccia G; Casabianca A; Magnani M; Buttò S; Levendal E; Ndimande JV; Asia B; Pillay Y; Garaci E; Monini P;
    Retrovirology; 2016 Jun; 13(1):34. PubMed ID: 27277839
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cellular immune responses in asymptomatic human immunodeficiency virus type 1 (HIV-1) infection and effects of vaccination with recombinant envelope glycoprotein of HIV-1.
    Gorse GJ; Simionescu RE; Patel GB
    Clin Vaccine Immunol; 2006 Jan; 13(1):26-32. PubMed ID: 16425996
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Autoproliferation in HIV-1-infected patients undergoing active HIV-1-specific immunotherapy.
    Trauger RJ; Giermakowska W; Wormsley S; Turner J; Jensen FC; Carlo DJ
    Clin Exp Immunol; 1995 Apr; 100(1):7-12. PubMed ID: 7697926
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reduced viral burden amongst high responder patients following HIV-1 p24 peptide-based therapeutic immunization.
    Kran AM; Sommerfelt MA; Sørensen B; Nyhus J; Baksaas I; Bruun JN; Kvale D
    Vaccine; 2005 Jul; 23(31):4011-5. PubMed ID: 15963359
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Polyfunctional CD4(+) T cell responses in HIV-1-infected viral controllers compared with those in healthy recipients of an adjuvanted polyprotein HIV-1 vaccine.
    Van Braeckel E; Desombere I; Clement F; Vandekerckhove L; Verhofstede C; Vogelaers D; Leroux-Roels G
    Vaccine; 2013 Aug; 31(36):3739-46. PubMed ID: 23707169
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Initial studies on active immunization of HIV-infected subjects using a gp120-depleted HIV-1 Immunogen: long-term follow-up.
    Levine AM; Groshen S; Allen J; Munson KM; Carlo DJ; Daigle AE; Ferre F; Jensen FC; Richieri SP; Trauger RJ; Parker JW; Salk PL; Salk J
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Apr; 11(4):351-64. PubMed ID: 8601221
    [TBL] [Abstract][Full Text] [Related]  

  • 34. T-helper-cell proliferative responses to whole-killed human immunodeficiency virus type 1 (HIV-1) and p24 antigens of different clades in HIV-1-infected subjects vaccinated with HIV-1 immunogen (Remune).
    Moss RB; Giermakowska W; Wallace MR; Savary J; Jensen F; Carlo DJ
    Clin Diagn Lab Immunol; 2000 Sep; 7(5):724-7. PubMed ID: 10973444
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of a HIV-1 lipopeptide antigen pulsed therapeutic dendritic cell vaccine.
    Cobb A; Roberts LK; Palucka AK; Mead H; Montes M; Ranganathan R; Burkeholder S; Finholt JP; Blankenship D; King B; Sloan L; Harrod AC; Lévy Y; Banchereau J
    J Immunol Methods; 2011 Feb; 365(1-2):27-37. PubMed ID: 21093448
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized controlled trial of HIV therapeutic vaccination using ALVAC with or without Remune.
    Angel JB; Routy JP; Tremblay C; Ayers D; Woods R; Singer J; Bernard N; Kovacs C; Smaill F; Gurunathan S; Sekaly RP
    AIDS; 2011 Mar; 25(6):731-9. PubMed ID: 21330911
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HIV-1-infected children on HAART: immunologic features of three different levels of viral suppression.
    Zaccarelli-Filho CA; Ono E; Machado DM; Brunialti M; Succi RC; Salomão R; Kallás EG; de Moraes-Pinto MI
    Cytometry B Clin Cytom; 2007 Jan; 72(1):14-21. PubMed ID: 17041945
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic vaccination using cationic liposome-adjuvanted HIV type 1 peptides representing HLA-supertype-restricted subdominant T cell epitopes: safety, immunogenicity, and feasibility in Guinea-Bissau.
    Román VR; Jensen KJ; Jensen SS; Leo-Hansen C; Jespersen S; da Silva Té D; Rodrigues CM; Janitzek CM; Vinner L; Katzenstein TL; Andersen P; Kromann I; Andreasen LV; Karlsson I; Fomsgaard A
    AIDS Res Hum Retroviruses; 2013 Nov; 29(11):1504-12. PubMed ID: 23634822
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Augmentation of HIV-1-specific T helper cell responses in chronic HIV-1 infection by therapeutic immunization.
    Robbins GK; Addo MM; Troung H; Rathod A; Habeeb K; Davis B; Heller H; Basgoz N; Walker BD; Rosenberg ES
    AIDS; 2003 May; 17(8):1121-6. PubMed ID: 12819512
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Functional restoration of human immunodeficiency virus and Epstein-Barr virus-specific CD8(+) T cells during highly active antiretroviral therapy is associated with an increase in CD4(+) T cells.
    Kostense S; Otto SA; Knol GJ; Manting EH; Nanlohy NM; Jansen C; Lange JM; van Oers MH; Miedema F; van Baarle D
    Eur J Immunol; 2002 Apr; 32(4):1080-9. PubMed ID: 11920575
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.